FindTrial
Sign In

PREDNISONA CINFA 10 MG COMPRIMIDOS

DRUG3 trials

Sponsors

Prevail Therapeutics Inc., ROXALL Medizin GmbH

Conditions

Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN)Moderate-to-severe allergic rhinitis / rhinoconjunctivitis due to olive pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelineType 1 Gaucher Disease (Peripheral/Non-neuronopathic Manifestations)

Phase 1

An Open-label, Dose-Finding, Phase 1/2 Study to Evaluate the Safety and Tolerability of a Single Intravenous Dose of LY3884961 in Subjects with Peripheral Manifestations of Gaucher Disease
SuspendedCTIS2022-500281-10-02
Prevail Therapeutics Inc.Type 1 Gaucher Disease (Peripheral/Non-neuronopathic Manifestations)
Start: 2023-10-18Target: 6Updated: 2025-09-11
A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN) (PROCLAIM)
SuspendedCTIS2022-502942-29-01
Prevail Therapeutics Inc.Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN)
Start: 2024-08-05Target: 15Updated: 2025-11-26

Phase 2

Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from Olea europaea pollen allergy
CompletedCTIS2024-511383-88-00
ROXALL Medizin GmbHModerate-to-severe allergic rhinitis / rhinoconjunctivitis due to olive pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline
Start: 2024-09-01End: 2025-10-14Target: 50Updated: 2024-07-11